ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Tharimmune, Inc. (THAR) stock surged +0.78%, trading at $1.29 on NASDAQ, up from the previous close of $1.28. The stock opened at $1.26, fluctuating between $1.28 and $1.47 in the recent session.
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Employees | 2 |
Beta | 1.3 |
Sales or Revenue | N/A |
5Y Sales Change% | 0% |
Fiscal Year Ends | N/A |
Sector | Healthcare |
Industry | Biotechnology |